Results 41 to 50 of about 21,252 (207)

Oral burning with dysphagia and weight loss [PDF]

open access: yes, 2015
Fibromyalgia is a disorder characterized by an abnormal pain regulation. Widespread pain, fatigue, and sleep disturbance are the prevalent symptoms.
CALO', LORENZO   +3 more
core   +1 more source

Clinical Characteristics of Intravenous Pantoprazole Consumption in Cardiac Intensive Care Unit

open access: yesPharmaceutical and Biomedical Research, 2021
Background: Proton Pump Inhibitors (PPIs) are the most common medicine for the treatment and prophylaxis of acid peptic conditions. The inappropriate use of the PPIs, mainly the intravenous form of pantoprazole may lead to excessive cost and unexpected ...
Gohar Eslami   +5 more
doaj  

Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

open access: yesActa Medica Iranica, 2023
The widespread inappropriate use of intravenous (IV) pantoprazole, due to its high cost, is a substantial issue. To improve its rational use, an order entry form (OEF) based on the institutional guideline, was implemented.
Maryam Taghizadeh-Ghehi   +5 more
doaj   +1 more source

Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer

open access: yesCell & Bioscience, 2018
Background We investigated the inhibitory effect of pantoprazole on signal transducer and activator of transcription 3 (STAT3) activity and invasiveness of gastric adenocarcinoma cells, and the role of SH2-containing protein tyrosine phosphatase 1 (SHP-1)
Jin Sung Koh   +7 more
doaj   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

open access: yesAdvanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang   +10 more
wiley   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres   +8 more
wiley   +1 more source

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. [PDF]

open access: yes, 2019
Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid suppression due to their irreversible inhibition of the hydrogen/potassium pump in the gastric parietal cells. They are widely prescribed and are considered safe for over-the-
Abagyan, Ruben   +4 more
core   +1 more source

Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
Sylvia D. Klomp   +6 more
wiley   +1 more source

Voriconazole pharmacokinetics in liver transplant recipients [PDF]

open access: yes, 2009
The objective of this study was to evaluate the pharmacokinetics of voriconazole and the potential correlations between pharmacokinetic parameters and patient variables in liver transplant patients on a fixed-dose prophylactic regimen.
Johnson, H. J.   +11 more
core   +2 more sources

Proton-pump inhibitor-induced bone loss is preventable by concomitant use of a long-acting somatostatin analogue [PDF]

open access: yesIranian Journal of Basic Medical Sciences
Objective(s): Long-term consumption of pump inhibitors causes osteoporosis. Some possible mechanisms are gastrin over-secretion and hypochlorhydria. Octreotide is a somatostatin analog that inhibits the secretion of many hormones such as gastrin.
Farhad Koohpeyma   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy